RNA Fusion Panel Testing
RNA fusion panel testing was successfully completed for 25 cases (Figure
1), revealing fusions in 13 tumor samples (52%; Figure 2). The majority
of these (n=8) were activating RET kinase fusions, including the
well-known NCOA4-RET fusions (also known as RET/PTC3 ) in 5
cases, and CCDC6-RET (also known as RET/PTC1 ) in 3 tumors
(Figure 3). Four other tumors harbored NTRK3 fusions, including
two ETV6-NTRK3 fusions, one EML4-NTRK3 fusion, and a novelVIM-NTRK3 fusion in one sample. Finally, one tumor was found to
harbor a MACF1-BRAF fusion. All fusion genes identified retained
the kinase domains of the oncogenic partners (RET , NTRK3 ,BRAF ).